Next Article in Journal
Emergence of Carbapenem-Resistant Gram-Negative Isolates in Hospital Settings in Djibouti
Next Article in Special Issue
Probable Three-Species In Vivo Transfer of blaNDM-1 in a Single Patient in Greece: Occurrence of NDM-1-Producing Klebsiella pneumoniae, Proteus mirabilis, and Morganella morganii
Previous Article in Journal
Antibiotic Resistance Changes in Gram-Positive Bacteria from Urine Cultures: Development Analysis in a Health Area of South-East Spain
Previous Article in Special Issue
Genetic Characterization of Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates in a Tertiary Hospital in Greece, 2018–2022
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Efficacy of Novel Combinations of Antibiotics against Multidrug-Resistant—New Delhi Metallo-Beta-Lactamase-Producing Strains of Enterobacterales

1
Medical Microbiology Laboratory, Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202001, India
2
Department of Public Health, University of Naples Federico II, 80131 Naples, Italy
*
Authors to whom correspondence should be addressed.
Antibiotics 2023, 12(7), 1134; https://doi.org/10.3390/antibiotics12071134
Submission received: 12 June 2023 / Revised: 26 June 2023 / Accepted: 29 June 2023 / Published: 30 June 2023

Abstract

:
The emergence of multidrug-resistance (MDR)—New Delhi metallo-beta-lactamase (NDM)-producing microorganisms—has become a serious concern for treating such infections. Therefore, we investigated the effective antimicrobial combinations against multidrug-resistant New Delhi metallo-beta-lactamase-producing strains of Enterobacterales. The tests were carried out using the 2D(two-dimensional) checkerboard method. Of 7 antimicrobials, i.e., doripenem (DRP), streptomycin (STR), cefoxitin (FOX), imipenem (IPM), cefotaxime (CTX), meropenem (MER), and gentamicin (GEN), 19 different combinations were used, and out of them, three combinations showed synergistic effects against 31 highly drug-resistant strains carrying blaNDM and other associated resistance markers. Changes in the minimum inhibitory concentration (MIC) values were interpreted using the test fractional inhibitory concentration index (FIC Index). The FIC Index values of these combinations were found in the range of 0.1562 to 0.5, which shows synergy, whereas no synergism was observed in the remaining antimicrobial combinations. We conclude that these antibiotic combinations can be analyzed in in vivo and pharmacological studies to establish an effective therapeutic approach.

1. Introduction

The emergence of multidrug-resistant (MDR) bacterial infections is one of the major worldwide problems having difficulty being treated. Metallo-β-lactamases (MBLs) and extended β- lactamases (ESBLs) are the major causes of resistance in bacteria against available antibiotics [1]. Antibiotic efficacy against many Gram-negative pathogens is increasingly compromised by the spread and emergence of MDR strains that produce β-lactamases. These pathogens can confer resistance to one or more carbapenems, cephalosporins, monobactam penicillin, or drugs that are routinely used in clinical practice [2]. Carbapenems are considered the last resort of antibiotics against infections caused by MDR gram-negative microorganisms that show stability and high resistance values through bacterial outer membranes [1]. The common mechanisms for the members of the Enterobacteriaceae family include the production of β- lactamases, efflux pumps, and modification of penicillin-binding proteins (PBPs). In some bacterial species, the combination of these pathways can result in significant resistance to carbapenems [3]. In contrast to monobactam, New Delhi Metallo- β-lactamases (NDM) are a form of MBL that can hydrolyze most β-lactams, including carbapenems. The primary antimicrobial medicines of choice for treating severe infections caused by Gram-negative bacteria are carbapenems. Clinically used β-lactamase inhibitors, such as avibactam, clavulanate, sulbactam, and tazobactam, cannot stop the hydrolysis of β-lactams by NDM enzymes. In 2008, a Swedish patient who had been hospitalized in New Delhi, India, was infected with a strain of Klebsiella pneumoniae that included NDM-1 for the first time [4]. Since then, NDM-1 has been detected in numerous Enterobacteriaceae, Acinetobacter, and Pseudomonas species. These infections are the major challenge for clinicians in treating critically ill patients. The risk factors for NDM-1 strains include the lack of effective antibiotics, the failure to recognize highly prevalent asymptomatic carriers, the absence of a routine phenotypic test for the detection of Metallo-beta lactamases, and the presence of MBL on plasmids with the potential to rearrange and spread through horizontal gene transfer [3]. Therefore, to overcome the resistance problem, several studies for the treatment of MDR bacterial infections can be observed with the combination of ≥2 antimicrobial agents [5,6]. In the current scenario of the emergence of antibiotic resistance, where all classes of antibiotics fail to treat infections, a combination of these available antibiotics may be one of the most intelligent ideas to subside infections. Antimicrobial combination therapies can increase their efficacy over monotherapy and decrease MDR-based infections in clinical settings. Hence, we proposed to screen a large number of combinations of these available antibiotics against a set of MDR strains of clinical origin that have already been characterized in our previous studies.

2. Results and Discussion

2.1. Minimum Inhibitory Concentration

The MICs of cefoxitin, doripenem, imipenem, and streptomycin against MDR strains carrying blaNDM and other associated resistance markers on a plasmid, were reported in the range between 4096 μg/mL and 128 μg/mL (Table 1). All these MDR strains have already been characterized for the presence of resistance markers in our laboratory, and these isolates were collected from the neonatal intensive care unit (NICU) of an Indian hospital [7,8,9,10,11,12,13].

2.2. Synergistic Effect of Antibiotic Combinations

MDR clinical strains harboring blaNDM and other associated resistance markers like blaOXA-1, blaCTX-M, blaAmpC, blaCMY-1, and blaSHV showed resistance toward doripenem (MIC ranges 256 μg/mL to 1024 μg/mL), imipenem (MIC ranges 128 μg/mL to 2048 μg/mL), cefoxitin (MIC ranges 256 μg/mL to 4096 μg/mL) and streptomycin (MIC ranges 512 μg/mL to 4096 μg/mL) which were previously well characterized in our laboratory (Table 1). To check the effect of these antibiotics in combination, a total of 19 combinations of different classes of antibiotics were tested by a 2D checkerboard microdilution assay. Of them, only three combinations were found to be most effective against the set of clinical strains (Table 1). These combinations belong to the classes of carbapenems, cephamycin, and aminoglycosides (doripenem with cefoxitin, doripenem with streptomycin, and imipenem with cefoxitin), showing synergy. It was observed that the MICs of doripenem decreased from 1024 μg/mL to 64 μg/mL, cefoxitin 4096 μg/mL to 64 μg/mL, and streptomycin 4096 μg/mL to 32 μg/mL (Table 1) in combination, and their FICI values were in the range of 0.156 to 0.5 (Table 1) for all highly resistant strains tested, which were found in synergistic range. Previously, a synergistic effect of doripenem in combination with cefoxitin and tetracycline in inhibiting blaNDM-1-producing bacterial strains was reported by our research group [14]. The synergistic interaction of antimicrobials allows the use of lower doses. Another combination of imipenem and cefoxitin was showing a synergistic effect, with FICI values in the range of 0.187 to 0.5 (Table 1). It has been previously reported that synergy is observed when the FICI value is ≤0.5 [14]. In this study, three combinations showed synergy. The FICI values of combinations were found to be 0.5 to 0.1562 (Table 1). Although several mechanism-based studies were performed earlier on the interaction of antibiotics with specific markers using biophysical and biochemical approaches [14,15,16]. Antibiotic combination therapy with ceftazidime/avibactam (CAZ/AVI) and aztreonam (ATM) was previously investigated for the treatment of infection with NDM producer Enterobacterales. The majority of Enterobacterales that are ATM resistant and NDM positive shows significant efficacies of the CAZ/AVI+ATM combination against them [17]. Another study demonstrated the effectiveness of the double carbapenem combination against Gram-negative bacteria through the in vitro synergistic activity of ertapenem and meropenem [18].
Although β-lactamase inhibitors have been crucial to fighting against β-lactam resistance in Gram-negative bacteria, their potency has been dwindling as a result of the development of numerous severe β-lactamases. Though it has a unique synergistic mechanism of action, a triple combination of β- lactam antibiotics meropenem, piperacillin, and tazobactam has been demonstrated to be an effective method for killing Methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in a mouse model [19].
The susceptibility pattern of blaNDM-producing bacteria may vary geographically depending on specific strains over time. In this study, all microorganisms present were NDM producers and showed high resistance values due to which synergy of antibiotics was not able to restore susceptibilities, but the combination values were in synergistic range, showing this combination can be used for the therapeutic approach.

3. Materials and Methods

3.1. Strain, Antibiotics and Chemicals

This study included 31 MDR clinical strains carrying blaNDM and other associated resistance markers to determine the minimum inhibitory concentration (MIC) and fractional inhibitory concentration index (FICI). These strains were obtained from NICU of a North Indian Hospital. These are ESBL- and MBL-producing strains with different resistant markers, as reported previously by our group [7,8,9,10,11,12,13]. The antibiotic resistance markers and MIC of these strains are presented in Table 1. Doripenem, cefoxitin, and imipenem were purchased from Sigma-Aldrich (Sigma, Milan, Italy). Streptomycin was purchased from Himedia (Mumbai, India). Mueller–Hinton broth was purchased from Himedia (Mumbai, India).

3.2. Combination of Antibiotics and MIC

The antibiotics used in this study were doripenem (DRP), streptomycin (STR), cefoxitin (FOX), imipenem (IPM), cefotaxime (CTX), meropenem (MER), and gentamicin (GEN). These antibiotics were used to prepare all possible combinations against highly resistant clinical strains. To examine the MIC of antibiotics for a set of clinical strains, the overnight-grown colonies were collected using a sterile loop and transferred into a tube containing 5 mL of Mueller–Hinton broth. This broth was incubated at 37 °C to obtain a final turbidity equivalent to that of 0.5 McFarland standards (108 CFU/mL) and diluted to 1:100 for the broth microdilution procedure. The strains were treated with decreasing drug concentrations from 4096 μg/mL to 0.5 μg/mL according to Clinical Laboratory Standards Institute (CLSI) guidelines [20].

3.3. D-Checkerboard Microdilution Assay to Determine FICI

A total of 19 different combinations of antibiotics were taken against 31 MDR clinical strains. A 2D checkerboard microdilution assay was performed using a 96-well microtiter plate. Serially diluted antibiotics were taken in concentrations less than, equal to, or greater than their MICs. To check their effect against MDR clinical stains, fractional inhibitory concentration indexes (FICI) were calculated. The FICI value ≤0.5 was defined as synergy, <4, indifference, and >4, antagonism [21].

4. Conclusions

The study revealed three combinations: doripenem with cefoxitin, doripenem with streptomycin, and imipenem with cefoxitin, which are effective against highly drug-resistant clinical strains carrying blaNDM and other associated resistance markers. Hence, we propose these novel combinations against highly drug resistant clinical strains of bacteria for further in vivo and pharmacological studies in order to establish effective infection control therapy.

Author Contributions

Conceptualization, A.U.K. and R.Z.; methodology, S.K.; validation, S.K. and A.M.; formal analysis, S.K. and A.M.; investigation, S.K. and A.M.; resources, A.U.K.; data curation, S.K. and A.M.; writing—original draft preparation, S.K.; writing—review and editing, A.U.K. and R.Z.; visualization, S.K.; supervision, A.U.K. and R.Z.; project administration, A.U.K.; funding acquisition, A.U.K. All authors have read and agreed to the published version of the manuscript.

Funding

The DBT: Government of India, grant numbers BT/PR40148/BTIS/137/20/2021 and HRD-16012/6/2020-AFS-DBT, is highly acknowledged for its support. This work was supported also by grant from the Italian Ministry of University and Research (MUR): PRIN2017 (Grant nr. 2017SFBER to R.Z.).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data are provided in the main text of the manuscript.

Conflicts of Interest

The authors declared no conflict of interest.

References

  1. Cherak, Z.; Loucif, L.; Moussi, A.; Bendjama, E.; Benbouza, A.; Rolain, J.M. Emergence of Metallo-β-Lactamases and OXA-48 Carbapenemase Producing Gram-Negative Bacteria in Hospital Wastewater in Algeria: A Potential Dissemination Pathway Into the Environment. Microb. Drug Resist. 2022, 28, 23–30. [Google Scholar] [CrossRef] [PubMed]
  2. Bush, K. Past and present perspectives on β-lactamases. Antimicrob. Agents Chemother. 2018, 62, e01076-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Khan, A.U.; Maryam, L.; Zarrilli, R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-β-lactamase (NDM): A threat to public health. BMC Microbiol. 2017, 17, 101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Yong, D.; Toleman, M.A.; Giske, C.G.; Cho, H.S.; Sundman, K.; Lee, K.; Walsh, T.R. Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 2009, 53, 5046–5054. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Almutairi, M.M. Synergistic activities of colistin combined with other antimicrobial agents against colistin-resistant Acinetobacter baumannii clinical isolates. PLoS ONE 2022, 17, e0270908. [Google Scholar] [CrossRef] [PubMed]
  6. Scudeller, L.; Righi, E.; Chiamenti, M.; Bragantini, D.; Menchinelli, G.; Cattaneo, P.; Giske, C.G.; Lodise, T.; Sanguinetti, M.; Piddock, L.J.; et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int. J. Antimicrob. Agents 2021, 57, 106344. [Google Scholar] [CrossRef] [PubMed]
  7. Ahmad, N.; Ali, S.M.; Khan, A.U. Co-existence of blaNDM-1 and blaVIM-1 producing Moellerella wisconsensis in NICU of North Indian Hospital. J. Infect. Dev. Ctries. 2020, 14, 228–231. [Google Scholar] [CrossRef] [PubMed]
  8. Ahmad, N.; Khalid, S.; Ali, S.M.; Khan, A.U. Occurrence of blaNDM variants among Enterobacteriaceae from a neonatal intensive care unit in a northern India hospital. Front. Microbiol. 2018, 9, 407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Khalid, S.; Ahmad, N.; Ali, S.M.; Khan, A.U. The outbreak of efficiently transferred carbapenem-resistant blaNDM producing gram-negative bacilli isolated from the neonatal intensive care unit of an Indian hospital. Microb. Drug Resist. 2020, 26, 284–289. [Google Scholar] [CrossRef] [PubMed]
  10. Ahmad, N.; Ali, S.M.; Khan, A.U. Molecular characterization of novel sequence type of carbapenem-resistant New Delhi Metallo-β-lactamase-1-producing Klebsiella pneumoniae in the neonatal intensive care unit of an Indian hospital. Int. J. Antimicrob. Agents 2019, 53, 525–529. [Google Scholar] [CrossRef] [PubMed]
  11. Ahmad, N.; Ali, S.M.; Khan, A.U. Detection of New Delhi metallo-β-lactamase variants NDM-4, NDM-5, and NDM-7 in Enterobacter aerogenes isolated from a neonatal intensive care unit of a North India Hospital: A first report. Microb. Drug Resist. 2018, 24, 161–165. [Google Scholar] [CrossRef] [PubMed]
  12. Ahmad, N.; Ali, S.M.; Khan, A.U. First reported New Delhi metallo-β-lactamase-1-producing Cedecea lapagei. Int. J. Antimicrob. Agents 2017, 49, 118–119. [Google Scholar] [CrossRef] [PubMed]
  13. Parvez, S.; Khan, A.U. Hospital sewage water: A reservoir for variants of New Delhi metallo- β-lactamase (NDM) and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. Int. J. Antimicrob. Agents 2018, 51, 82–88. [Google Scholar] [CrossRef] [PubMed]
  14. Maryam, L.; Khalid, S.; Ali, A.; Khan, A.U. Synergistic effect of doripenem in combination with cefoxitin and tetracycline in inhibiting NDM-1-producing bacteria. Future Microbiol. 2019, 14, 671–689. [Google Scholar] [CrossRef] [PubMed]
  15. Hasan, S.; Ali, S.Z.; Khan, A.U. Novel combinations of antibiotics to inhibit extended-spectrum β-lactamase and Metallo-β-lactamase producers in vitro: A synergistic approach. Future Microbiol. 2013, 8, 939–944. [Google Scholar] [CrossRef] [PubMed]
  16. Shakil, S.; Khan, R.; Zarrilli, R.; Khan, A.U. Aminoglycosides versus bacteria–a description of the action, resistance mechanism, and nosocomial battleground. J. Biomed. Sci. 2008, 15, 5–14. [Google Scholar] [CrossRef] [PubMed]
  17. Rawson, T.M.; Brzeska-Trafny, I.; Maxfield, R.; Almeida, M.; Gilchrist, M.; Gonzalo, X.; Moore, L.S.; Donaldson, H.; Davies, F. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection. J. Glob. Antimicrob. Resist. 2022, 29, 558–562. [Google Scholar] [CrossRef] [PubMed]
  18. Lu, J.; Qing, Y.; Dong, N.; Liu, C.; Zeng, Y.; Sun, Q.; Shentu, Q.; Huang, L.; Wu, Y.; Zhou, H.; et al. Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria. Saudi Pharm. J. 2022, 30, 849–855. [Google Scholar] [CrossRef] [PubMed]
  19. Bush, K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int. J. Antimicrob. Agents 2015, 46, 483–493. [Google Scholar] [CrossRef] [PubMed]
  20. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 28th Informational Supplement; CLSI document M100-S29; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2019. [Google Scholar]
  21. Doern, C.D. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J. Clin. Microbiol. 2014, 52, 4124–4128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Table 1. Minimum Inhibitory concentrations and synergistic effects of doripenem, cefoxitin, imipenem, and streptomycin antibiotics against 31 MDR-NDM-producing clinical strains.
Table 1. Minimum Inhibitory concentrations and synergistic effects of doripenem, cefoxitin, imipenem, and streptomycin antibiotics against 31 MDR-NDM-producing clinical strains.
StrainsResistance MarkersMIC µg/mLMIC µg/mL
FIC Index 5
Ref.
DRP 1FOX 2IMP 3STP 4DRP + FOXDRP + STPIMP + FOX
AK-33 Escherichia coliNDM-4, OXA-1, CTX-M, Amp C512204810242048128 + 512
0.5
128 + 256
0.375
128 + 256
0.25
[13]
AK-35 Escherichia coliNDM-7, OXA-11024204810242048128 + 256
0.25
128 + 128
0.1875
256 + 512
0.5
[13]
AK-37 Escherichia coliNDM-1, CMY-139, OXA-1, CTX-M10241024512512128 + 128
0.375
256 + 128
0.5
256 + 128
0.5
[13]
AK-83 Escherichia coliNDM-7, OXA-1, SHV-151240961024204864 + 512
0.25
128 + 512
0.5
128 + 512
0.25
[8]
AK-66
Klebsiella pneumoniae
NDM-1, OXA-1, OXA-9, CMY-1256102410242048128 + 256
0.375
256 + 256
0.25
128 + 512
0.1875
[8]
AK-102
Klebsiella pneumoniae
NDM-5, OXA-1, OXA-9, CMY-41024204810242048128 + 512
0.375
64 + 512
0.3125
64 + 256
0.1875
[8]
AK-121
Klebsiella pneumoniae
NDM-151210245121024128 + 256
0.5
64 + 256
0.375
128 + 256
0.5
[10]
AK-125
Klebsiella pneumoniae
NDM-1512102410242048128 + 256
0.5
64 + 256
0.25
128 + 256
0.375
[10]
AK-130
Klebsiella pneumoniae
NDM-1512256512102464 + 64
0.375
128 + 128
0.375
128 + 64
0.5
[10]
AK-140
Klebsiella pneumoniae
NDM-1, OXA-481024102420482048128 + 256
0.375
256 + 512
0.5
512 + 128
0.375
[10]
AK-142
Klebsiella pneumoniae
NDM-151210245122048128 + 526
0.5
64 + 512
0.375
128 + 128
0.25
[10]
AK-144
Klebsiella pneumoniae
NDM-1512204810241024128 + 512
0.25
64 + 128
0.25
512 + 512
0.25
[10]
AK-147
Klebsiella pneumoniae
NDM-1, OXA-481024204820481024128 + 512
0.375
64 + 128
0.1875
512 + 512
0.5
[10]
AK-149
Klebsiella pneumoniae
NDM-1, OXA-481024204820482048128 + 512
0.375
512 + 128
0.375
256 + 512
0.375
[10]
AK-158
Klebsiella pneumoniae
NDM-51024204820482048128 + 256
0.25
64 + 512
0.3125
512 + 512
0.5
[10]
AK-100
Klebsiella oxytoca
NDM-4, OXA-1, OXA-91024409610242048256 + 256
0.3125
256 + 512
0.5
128 + 512
0.25
[8]
AK-67
Enterobacter aerogenes
NDM-1, OXA-1, SHV-2102420481024204864 + 128
0.1875
128 + 64
0.1562
32 + 64
0.3125
[8]
AK-93
Enterobacter aerogenes
NDM-4, OXA-1, OXA-9, SHV-15121024256102464 + 64
0.185
128 + 128
0.375
32 + 64
0.25
[11]
AK-95
Enterobacter aerogenes
NDM-5, OXA-1, OXA-9, CMY-1492561024256102464 + 128
0.375
64 + 256
0.5
32 + 256
0.375
[11]
AK-96
Enterobacter aerogenes
NDM-7, OXA-1, OXA-9, CMY-1452561024256204864 + 128
0.375
32 + 256
0.375
64 + 256
0.5
[11]
AK-108
Enterobacter cloacae
NDM-4, OXA-1, OXA-9, CMY-14951220485121024128 + 256
0.375
128 + 256
0.5
64 + 256
0.25
[8]
AK-154
Acinetobacter baumannii
NDM-51024204810242048128 + 256
0.25
128 + 256
0.25
64 + 256
0.1875
[9]
AK-42
Citrobacter freundii
NDM-1, CMY-42, OXA-1, CTX-M, AmpC1024409610244096256 + 1024
0.5
256 + 512
0.375
128 + 1024
0.375
[13]
AK-58
Citrobacter freudii
NDM-7, CMY-2, OXA-1, CTX-M2561024128204832 + 256
0.375
64 + 512
0.5
32 + 128
0.375
[13]
AK-82
Citrobacter freundii
NDM-4, OXA-9, SHV-1, CMY-149512409620482048128 + 1024
0.5
64 + 256
0.25
128 + 512
0.1875
[8]
AK-48
Citrobacter braakii
NDM-4, CMY-4, OXA-48512102410244096128 + 256
0.5
128 + 512
0.375
128 + 128
0.25
[13]
AK-49
Citrobacter farmer
NDM-4, CMY-4, OXA-4825610241024204864 + 256
0.5
128 + 1024
0.5
128 + 128
0.25
[13]
AK-68
Cedecea lapagei
NDM-1, CTX-M, SHV, TEM51210245121024128 + 256
0.5
128 + 256
0.5
128 + 128
0.375
[12]
AK-152
Cedecea davisae
NDM-11024204810241024128 + 256
0.25
128 + 256
0.375
64 + 256
0.1875
[9]
AK-65
Shigella boydii
NDM-5, CMY-42, OXA-1, CTX-M10242048128204864 + 64
0.125
128 + 128
0.1875
32 + 128
0.3125
[13]
AK-92
Moellerella wisconsensis
NDM-151210242562048128 + 256
0.5
64 + 256
0.25
64 + 128
0.375
[7]
1 DRP—doripenem; 2 FOX—cefoxitin; 3 STP—streptomycin; 4 I MP—imipenem; 5 FIC Index—Fractional Inhibitory Concentration Index.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Khalid, S.; Migliaccio, A.; Zarrilli, R.; Khan, A.U. Efficacy of Novel Combinations of Antibiotics against Multidrug-Resistant—New Delhi Metallo-Beta-Lactamase-Producing Strains of Enterobacterales. Antibiotics 2023, 12, 1134. https://doi.org/10.3390/antibiotics12071134

AMA Style

Khalid S, Migliaccio A, Zarrilli R, Khan AU. Efficacy of Novel Combinations of Antibiotics against Multidrug-Resistant—New Delhi Metallo-Beta-Lactamase-Producing Strains of Enterobacterales. Antibiotics. 2023; 12(7):1134. https://doi.org/10.3390/antibiotics12071134

Chicago/Turabian Style

Khalid, Shamsi, Antonella Migliaccio, Raffaele Zarrilli, and Asad U. Khan. 2023. "Efficacy of Novel Combinations of Antibiotics against Multidrug-Resistant—New Delhi Metallo-Beta-Lactamase-Producing Strains of Enterobacterales" Antibiotics 12, no. 7: 1134. https://doi.org/10.3390/antibiotics12071134

APA Style

Khalid, S., Migliaccio, A., Zarrilli, R., & Khan, A. U. (2023). Efficacy of Novel Combinations of Antibiotics against Multidrug-Resistant—New Delhi Metallo-Beta-Lactamase-Producing Strains of Enterobacterales. Antibiotics, 12(7), 1134. https://doi.org/10.3390/antibiotics12071134

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop